Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
$4.17
+1.7%
$2.68
$1.03
$4.29
$835.41M1.546.63 million shs7.66 million shs
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
$2.35
-2.1%
$2.26
$1.11
$5.00
$638.74M1.91.55 million shs1.35 million shs
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
$6.65
-0.9%
$6.70
$6.08
$16.76
$680.14M-1.261.29 million shs1.05 million shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.58
+0.2%
$12.82
$7.09
$27.38
$157.98M0.45134,697 shs64,103 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
+1.71%+16.81%+51.64%+178.00%+169.03%
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-2.08%-6.75%0.00%+74.07%-49.89%
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-0.89%-8.02%-1.19%-16.14%-53.53%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+0.24%-8.24%-6.12%+5.63%+53.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
3.005 of 5 stars
4.71.00.00.02.01.70.6
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
2.3377 of 5 stars
3.52.00.00.00.63.30.6
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
2.2526 of 5 stars
3.63.00.00.01.12.50.0
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.7998 of 5 stars
3.50.01.72.71.12.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
3.40
Buy$11.25169.78% Upside
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
3.00
Buy$9.32296.60% Upside
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
3.14
Buy$29.00336.09% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50142.45% Upside

Current Analyst Ratings Breakdown

Latest LFVN, DAWN, ATAI, and AUTL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/30/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $15.00
7/29/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$14.00
7/28/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $11.00
7/21/2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
7/2/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Aegis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/2/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$11.00 ➝ $12.00
6/12/2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/20/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$5.00
5/20/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/13/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/7/2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$25.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
$1.86M448.42N/AN/A$0.69 per share6.04
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
$10.12M61.80N/AN/A$1.61 per share1.46
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
$131.16M5.14N/AN/A$4.99 per share1.33
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.79$0.88 per share14.23$2.05 per share6.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$149.27M-$0.91N/AN/AN/AN/A-102.10%-77.55%8/12/2025 (Estimated)
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$220.66M-$0.88N/AN/AN/AN/A-52.82%-29.67%8/12/2025 (Estimated)
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-$95.50M-$0.71N/AN/AN/A-42.66%-14.98%-13.04%8/5/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.23N/A4.12%34.67%15.24%8/27/2025 (Estimated)

Latest LFVN, DAWN, ATAI, and AUTL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/27/2025Q4 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.17N/AN/AN/A$57.93 millionN/A
8/12/2025Q2 2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$0.13N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$0.2329N/AN/AN/A$12.92 millionN/A
8/5/2025Q2 2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-$0.35N/AN/AN/A$35.55 millionN/A
5/14/2025Q1 2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$0.19-$0.15+$0.04-$0.15N/A$1.56 million
5/8/2025Q1 2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 million
5/6/2025Q1 2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
N/AN/AN/AN/AN/A
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
N/AN/AN/AN/AN/A
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.43%N/A26.09%3 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
0.08
4.07
4.07
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
N/A
9.24
9.02
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
N/A
10.62
10.55
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98

Institutional Ownership

CompanyInstitutional Ownership
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
28.41%
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
72.83%
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
87.95%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%

Insider Ownership

CompanyInsider Ownership
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
26.80%
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
25.70%
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
6.20%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
80200.34 million146.65 millionOptionable
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
330266.14 million197.74 millionOptionable
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
60101.36 million95.08 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable

Recent News About These Companies

LifeVantage To Open Iceland Market

New MarketBeat Followers Over Time

Media Sentiment Over Time

atai Life Sciences stock logo

atai Life Sciences NASDAQ:ATAI

$4.17 +0.07 (+1.71%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$4.16 -0.01 (-0.36%)
As of 08/1/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Autolus Therapeutics stock logo

Autolus Therapeutics NASDAQ:AUTL

$2.35 -0.05 (-2.08%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.35 0.00 (-0.21%)
As of 08/1/2025 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Day One Biopharmaceuticals stock logo

Day One Biopharmaceuticals NASDAQ:DAWN

$6.65 -0.06 (-0.89%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$6.64 -0.01 (-0.08%)
As of 08/1/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.58 +0.03 (+0.24%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$12.57 -0.01 (-0.08%)
As of 08/1/2025 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.